Ya Cao1,2, Haitao Huang2,3, Zhenxin Wang1,2, Guangbo Zhang1. 1. a Jiangsu Key Laboratory of Clinical Immunology, The First Affiliated Hospital of Soochow University , Suzhou , China. 2. b Department of Medical Oncology , The First Affiliated Hospital of Soochow University , Suzhou , China. 3. c Department of Thoracic Surgery , The First Affiliated Hospital of Soochow University , Suzhou , China.
Abstract
AIMS: To investigate the clinical significance of tumor tissue-infiltrating chemokines expression in non-small cell lung cancer (NSCLC) microenvironment. MATERIALS AND METHODS: Fresh tissue samples were acquired from 50 patients with NSCLC after operation. Then, we quantified the total protein with the BCA Protein Assay Kit and tested 13 chemotactic factors in paired samples including tumor tissues, tumor adjacent tissues, and normal tissues with the CBA Kit. RESULTS: We found that the chemokine CC subfamily of MCP-1, MIP-1α, MIP-1β, and MIP-3α and the chemokine CXC subfamily of IL-8, GROα, IP-10, and MIG expressions in tumor tissues were significantly higher than those in tumor-adjacent tissues and normal tissues. However, regulated upon activation normal T cell expressed and secreted (RANTES), human thymus activation regulated chemokine (TARC), chemokine (C-C motif) ligand 11 (CCL11), interferon-inducible T cell alpha chemoattractant (I-TAC), and ENA-78 expressions did not show significant difference. Analyzing the influence of chemokine expression level in tumor tissues on disease progression, we found the median progression-free survival (mPFS) of patients with GROαhigh was significantly lower than those with GROαlow; mPFS of patients with IP-10low was significantly lower than those with IP-10high; and mPFS of patients with MIGlow was significantly lower than those with MIGhigh. However, MCP-1, MIP-1α, MIP-1β, MIP-3α, and IL-8 had no significant value to elevate the mPFS of patients with NSCLC. CONCLUSION: In summary, tumor tissue-infiltrating CXC chemokines, GROαhigh, IP-10low, and MIGlow in the tumor microenvironment can be used as potential indicators for the progression of NSCLC.
AIMS: To investigate the clinical significance of tumor tissue-infiltrating chemokines expression in non-small cell lung cancer (NSCLC) microenvironment. MATERIALS AND METHODS: Fresh tissue samples were acquired from 50 patients with NSCLC after operation. Then, we quantified the total protein with the BCA Protein Assay Kit and tested 13 chemotactic factors in paired samples including tumor tissues, tumor adjacent tissues, and normal tissues with the CBA Kit. RESULTS: We found that the chemokine CC subfamily of MCP-1, MIP-1α, MIP-1β, and MIP-3α and the chemokine CXC subfamily of IL-8, GROα, IP-10, and MIG expressions in tumor tissues were significantly higher than those in tumor-adjacent tissues and normal tissues. However, regulated upon activation normal T cell expressed and secreted (RANTES), human thymus activation regulated chemokine (TARC), chemokine (C-C motif) ligand 11 (CCL11), interferon-inducible T cell alpha chemoattractant (I-TAC), and ENA-78 expressions did not show significant difference. Analyzing the influence of chemokine expression level in tumor tissues on disease progression, we found the median progression-free survival (mPFS) of patients with GROαhigh was significantly lower than those with GROαlow; mPFS of patients with IP-10low was significantly lower than those with IP-10high; and mPFS of patients with MIGlow was significantly lower than those with MIGhigh. However, MCP-1, MIP-1α, MIP-1β, MIP-3α, and IL-8 had no significant value to elevate the mPFS of patients with NSCLC. CONCLUSION: In summary, tumor tissue-infiltrating CXC chemokines, GROαhigh, IP-10low, and MIGlow in the tumor microenvironment can be used as potential indicators for the progression of NSCLC.
Authors: Ellen J Spartz; Matthew Wheelwright; Tetyana Mettler; Khalid Amin; Nabeel Azeem; Mohamed Hassan; Jacob Ankeny; James V Harmon Journal: Clin Case Rep Date: 2022-07-14
Authors: Charlotte Dahlem; Wei Xiong Siow; Maria Lopatniuk; William K F Tse; Sonja M Kessler; Susanne H Kirsch; Jessica Hoppstädter; Angelika M Vollmar; Rolf Müller; Andriy Luzhetskyy; Karin Bartel; Alexandra K Kiemer Journal: Cancers (Basel) Date: 2020-05-19 Impact factor: 6.639